New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer ResearchBusiness Wire • 02/14/25
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU SymposiumBusiness Wire • 02/11/25
New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder CancerBusiness Wire • 02/05/25
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025Business Wire • 02/04/25
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio NowZacks Investment Research • 12/27/24
4 Healthcare Technology Innovators to Invest in Before the New YearZacks Investment Research • 12/19/24
Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025Zacks Investment Research • 12/16/24
Why Veracyte, With 55% Growth In 2024, Is An Outlier In Cancer DiagnosticsInvestors Business Daily • 12/12/24
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and InogenZacks Investment Research • 12/12/24
Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer GuidelinesBusiness Wire • 12/05/24